| Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients D Davar, AK Dzutsev, JA McCulloch, RR Rodrigues, JM Chauvin, ... Science 371 (6529), 595-602, 2021 | 1174 | 2021 |
| Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma YG Najjar, AV Menk, C Sander, U Rao, A Karunamurthy, R Bhatia, S Zhai, ... JCI insight 4 (5), 2019 | 204 | 2019 |
| Myeloid-derived suppressor cell subset accumulation in renal cell carcinoma parenchyma is associated with intratumoral expression of IL1β, IL8, CXCL5, and Mip-1α YG Najjar, P Rayman, X Jia, PG Pavicic Jr, BI Rini, C Tannenbaum, J Ko, ... Clinical Cancer Research 23 (9), 2346-2355, 2017 | 189 | 2017 |
| Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer YG Najjar, JH Finke Frontiers in oncology 3, 49, 2013 | 179 | 2013 |
| Anti‐PD‐1 synergizes with cyclophosphamide to induce potent anti‐tumor vaccine effects through novel mechanisms M Mkrtichyan, YG Najjar, EC Raulfs, MY Abdalla, R Samara, ... European journal of immunology 41 (10), 2977-2986, 2011 | 171 | 2011 |
| A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma YG Najjar, K Mittal, P Elson, L Wood, JA Garcia, R Dreicer, BI Rini European Journal of Cancer 50 (6), 1084-1089, 2014 | 134 | 2014 |
| Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study YG Najjar, K Navrazhina, F Ding, R Bhatia, K Tsai, K Abbate, B Durden, ... Journal for immunotherapy of cancer 8 (1), 2020 | 101 | 2020 |
| Characteristics of the tumor microenvironment that influence immune cell functions: hypoxia, oxidative stress, metabolic alterations RC Augustin, GM Delgoffe, YG Najjar Cancers 12 (12), 3802, 2020 | 95 | 2020 |
| Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations LH Butterfield, YG Najjar Nature Reviews Immunology 24 (6), 399-416, 2024 | 85 | 2024 |
| Novel agents in renal carcinoma: a reality check YG Najjar, BI Rini Therapeutic advances in medical oncology 4 (4), 183-194, 2012 | 78 | 2012 |
| B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets M Mkrtichyan, YG Najjar, EC Raulfs, L Liu, S Langerman, G Guittard, ... The Journal of Immunology 189 (5), 2338-2347, 2012 | 62 | 2012 |
| Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma S Roy, D Pradhan, WL Ernst, S Mercurio, Y Najjar, R Parikh, AV Parwani, ... Modern Pathology 30 (8), 1133-1143, 2017 | 51 | 2017 |
| Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities Z Eroglu, SL Holmen, Q Chen, NI Khushalani, R Amaravadi, R Thomas, ... Pigment cell & melanoma research 32 (3), 458-469, 2019 | 45 | 2019 |
| Immune-related adverse events in PD-1 treated melanoma and impact upon anti-tumor efficacy: a real world analysis ML Bastacky, H Wang, D Fortman, Z Rahman, GP Mascara, T Brenner, ... Frontiers in Oncology 11, 749064, 2021 | 32 | 2021 |
| Obesity is associated with altered tumor metabolism in metastatic melanoma AW Hahn, AV Menk, DB Rivadeneira, RC Augustin, M Xu, J Li, X Wu, ... Clinical Cancer Research 29 (1), 154-164, 2023 | 24 | 2023 |
| Neoadjuvant pembrolizumab and high-dose IFNα-2b in resectable regionally advanced melanoma YG Najjar, D McCurry, H Lin, Y Lin, Y Zang, D Davar, A Karunamurthy, ... Clinical Cancer Research 27 (15), 4195-4204, 2021 | 24 | 2021 |
| 523 Preliminary clinical experience with XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors E Shum, M Reilley, Y Najjar, A Daud, J Thompson, J Baranda, RD Harvey, ... Journal for Immunotherapy of Cancer 9 (Suppl 2), 2021 | 18 | 2021 |
| Metformin is associated with improved clinical outcomes in patients with melanoma: a retrospective, multi-institutional study RC Augustin, Z Huang, F Ding, S Zhai, J McArdle, A Santisi, M Davis, ... Frontiers in Oncology 13, 1075823, 2023 | 17 | 2023 |
| An updated analysis of 4 randomized ECOG trials of high‐dose interferon in the adjuvant treatment of melanoma YG Najjar, M Puligandla, SJ Lee, JM Kirkwood Cancer 125 (17), 3013-3024, 2019 | 17 | 2019 |
| Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab YG Najjar, F Ding, Y Lin, R VanderWeele, LH Butterfield, AA Tarhini Journal of translational medicine 15, 1-9, 2017 | 14 | 2017 |
